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The body, it seems, is over-cautious. 
Faced with the insult of a stroke, heart 
attack or neurodegenerative disease, it 
will sacrifice cells that have minimal 
damage and could easily be 
rehabilitated. Idun Pharmaceuticals. 
Inc. (La Jolla, California) believes that 
it can intervene in this process by 
turning off the programmed cell death, 
or apoptosis, that kills the cells. The 
company also aims to trigger apoptosis 
in cancer cells. Both projects are 
focused on small-molecule drugs, but 
they will be helped by Idun’s licensed 
technology for getting proteins into 
cells - a technology that will, at least 
according to its inventor, revolutionize 
the pharmaceutical industry. 
Move fast and recruit aggressively 
In November 1993, Robert Horvitz of 
the Massachusetts Institute of 
Technology (Cambridge, 
Massachusetts) announced the cloning 
of CED3, an apoptosis-promoting 
gene from the worm Caenorhabditis 
degans. CED3 was most similar to 
human interleukin-1 converting 
enzyme (ICE), which cleaves the pro- 
inflammatory messenger interleukin-1 
to yield its active form. 
Horvitz and his collaborators were 
not put off by this odd similarity, and 
in 1993 they formed the cell-death 
company Idun. An early experiment 
showed that an ICE inhibitor could, 
indeed, block neuronal apoptosis. 
John Reed of the Burnham 
Institute (La Jolla, California) was 
looking at the flip side of apoptosis - 
the anti-death gene Bcl-2 - but he 
came to the same conclusion as 
Horvitz: this field needed a biotech 
company. Reed’s company was named 
Apoptech Inc., but it had a brief life. 
“The two companies were talking to 
the same people for the same 
licenses, so they merged in 1994 to 
form Idun,” says Steven Mento, now 
president and CEO of Idun. 
The combined company quickly 
lined up a stellar scientific advisory 
board, which includes Horvitz, Reed, 
Stanley Korsmeyer (Harvard Medical 
School, Boston, Massachusetts), Craig 
Thompson (University of Chicago, 
Illinois), Martin Raff (University 
College London) and Carlo Croce 
(Jefferson Medical College, 
Philadelphia, Pennsylvania). And with 
collaborative research agreements and 
aggressive licensing, Idun now has 
issued or pending patents for Bcl-2 
and related proteins, and for six of the 
cell-death proteases, or caspases 
(caspases 3, 6, 7, 8,9 and 10). 
“They have been at the forefront 
of some of the advances in this 
field,” says Scott Kaufmann (Mayo 
Clinic, Rochester, Minnesota), who is 
not affiliated with Idun. “They have 
selective inhibitors that nobody else 
has, and they have been more than 
keeping up with the enzymology as 
investigators clone new caspases.” 
The case for caspase therapy 
If cells are broken open by a crush, 
burn or chemical injury, or if they are 
completely deprived of oxygen. they 
die by necrosis. Thus the cells at the 
center of a region of stroke or heart 
attack-cells that have had their 
oxygen supply completely cut off - 
will mainly die of necrosis. But cells 
that are close to but not at the site of 
insult may suffer only a shortage of 
oxygen. Cells that are even more 
distant may be swept away by an over- 
enthusiastic immune system intent on 
clearing up an injured site. Anti- 
caspase therapy is aimed at these 
surrounding cell populations. Rodent 
models of stroke suggest that the 
number of dying cells can be halved 
by broad spectrum caspase inhibitors, 
which are thought to shut down both 
apoptosis and inflammation processes. 
Idun plans to test broad-specificity 
caspase inhibitors for acute conditions 
like stroke, but these inhibitors are 
unlikely to work in the long-term for 
neurodegenerative diseases. The 
body needs to maintain some level of 
cell death as an essential part of life, 
to eliminate unwanted cells in the 
immune system and the gut. “Where 
you only have to give the inhibitor 
for a day or three I think [caspase 
therapy] is very promising,” says 
Kaufmann. As to whether longer- 
term therapy will work, he says, “I 
don’t know if the field is far enough 
along to know.” 
This was one reason that Elan 
Pharmaceuticals, plc (Dublin, 
Ireland) decided to get out of caspase 
therapy. “We never felt that caspase 
inhibition as a chronic therapy was 
reasonable,” says Guriq Basi, a 
principal scientist at Elan. 
One solution is to make specific 
inhibitors that only target certain 
caspases and therefore, perhaps, 
certain cell types. When Elan 
decided to stop caspase research two 
years ago, says Basi, “there were 
multiple [caspases] and it was 
difficult to specify the target.” The 
numbers of caspases has only grown 
since then. Kevin Tomaselli. vice- 
president of science and technology 
at Idun, admits that “there is no 
human disease for which I could 
state with a high degree of certainty 
that you need to target one specific 
caspase. The information of which 
caspases to target is in the works.” 
Idun is making small-molecule 
inhibitors that are specific for particular 
caspases (it already has some); it can 
then test them in in vitro systems that 
mimic conditions like hypoxia or 
neurodegeneration. Such testing can 
indicate which caspases make good 
targets, but only animal testing will 
indicate which caspases need to be 
avoided because of side-effects. 
Caspases work in self-amplifying 
cascades of cleavage and activation, so 
Idun must determine where caspases 
lie on the pathway and where the 
pathway reaches the point of no 
return. “In cytokine-induced apoptosis 
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Table 1 
Selected companies interested in ICE, caspase or apoptosis research 
Company Progress or objectives 
Vertex Pharmaceuticals, Inc. 
Merck & Co., Inc. 
Millennium Pharmaceuticals, Inc. 
Cytovia, Inc. 
BASF Bioresearch Corporation 
LXR Biotechnology Inc. 
Genta Inc. 
Designed the first caspase-related drug to go into phase I 
clinical trials - an inhibitor of interleukin-1 converting enzyme 
(ICE, or caspase 1) - for inflammation. Determined ICE 
structure and collaborated on caspase 9 knockout mouse. 
Co-discovered ICE, still interested in inflammation but also 
acute and chronic caspase inhibition for stroke, heart attack 
and neurodegeneration. Merck and ldun patents overlap. 
Program started recently. Have issued patent for inhibitory 
forms of caspase 8 that lack the protease domain. 
Spin-off from CoCencys, Inc. Cell-based screening system 
for caspase inhibitors uses flurogenic substrates that 
penetrate and then stay inside cells. Collaborating with 
Aurora Biosciences Corporation. 
Solved ICE structure; interested in caspase inhibitors. 
Discovered the secreted apoptosis-related protein (SARP-1) 
in the anti-apoptotic conditioned media of quiescent cells. 
Gene therapy of SARP-1 with Rhone-Poulenc Rorer Gencell. 
Antisense Bcl-2 for non-Hodgkin’s lymphoma. 
you can completely prevent apoptosis 
with caspase inhibitors,” says 
Tomaselli, for in this instance caspases 
are known to lie near the top of the 
pathway. “For other cell-death stimuli, 
the caspase inhibitor may be 
functioning far enough downstream 
that there has [already] been 
irreparable damage that the caspase 
inhibitors cannot reverse,” he says. An 
example of possible damage is the 
release of apoptotic inducers from the 
mitochondria, such as cytochrome c 
and the recently identified AIF 
(apoptosis-inducing factor). 
Vertex Pharmaceuticals, Inc. 
(Cambridge, Massachusetts) is the 
first to get a caspase-related drug into 
trials (Table 1); Idun should get their 
turn sometime in 2000. Their first 
target is acute exacerbations of 
alcoholic hepatitis, closely followed 
by stroke (the latter in collaboration 
with Novartis of Basel, Switzerland). 
Killing off tumor cells 
Tumor cells are often faced with a 
poor blood supply, an inadequate 
extracellular matrix, and DNA 
damage, and yet still they live. 
“Tumor cells harbor multiple genetic 
lesions that are chronically telling the 
cells to kill themselves, and the cell 
would be dead if it didn’t upregulate 
survival signals,” says Tomaselli. This 
reasoning prompted Idun to search for 
molecules that disrupt the interaction 
of Bcl-2 with its pro-apoptotic partners 
such as Bax. With Bcl-2 inactive, Bax 
can induce apoptosis. 
Still, nobody can be sure that 
tumor cells will be preferentially 
susceptible to anti-Bcl-2 drugs. 
Kaufmann does not think this should 
hold Idun back. “There is no reason to 
think that there [should be] a 
therapeutic index for DNA-damaging 
agents, but for patients who have the 
right tumors those drugs work,” he 
says. “In my inexperienced youth I 
would’ve laughed at John Reed and 
Idun, but I think criticizing this 
approach [without data] is too hasty.” 
The challenge for now is to come 
up with a small-molecule inhibitor 
that can disrupt a protein-protein 
interaction. The only known 
inhibitors are peptides of 14-16 
amino acids. Idun has enlisted the 
SAR by NMR technique of Abbott 
Laboratories (Abbott Park, Illinois; 
see Chena. Biol. 4, 231-232) to piece 
together a large inhibitor from many 
smaller binding molecules. 
Getting proteins into cells 
In 1988, two groups showed that a 
fragment of the HIV Tat protein 
could cross membranes and take 
attached proteins with it. This 
evolutionary fluke is irrelevant to HIV 
biology. It does not require any 
protein component or energy source. 
Unfortunately the reproducibility 
of transduction was, at best, poor. 
“This was almost thought to be a 
weird artifact,” says Steven Dowdy 
(Washington University, St. Louis, 
Missouri). “It never progressed to a 
very usable system.” 
Dowdy decided that everyone 
was doing one thing to foil the 
method - they were using correctly 
folded protein. “We took a totally 
blasphemous approach of using 
denatured proteins,” says Dowdy. 
His “magic column,” with a sudden 
drop from 4M to OM urea. did the 
trick, perhaps by creating an 
unfolded protein that can ‘thread’ 
through membranes. 
Recently, Dowdy transduced cells 
with a modified caspase precursor that 
is cleaved by HIV protease to form an 
active enzyme. Infected cells are killed; 
uninfected cells are left unharmed. 
The technology should work for other 
infectious agents that depend on 
proteases, like hepatitis C and malaria. 
Idun licensed the technology 
from Washington University and is 
seeking a partner for the caspase 
application; other applications will be 
sub-licensed. Dowdy thinks there 
will be plenty of takers. “This is the 
tip of the iceberg of what you can do 
with protein therapy,” he says. Until 
now protein therapy has been limited 
to proteins that act outside the cell; 
the inside of the cell has been the 
domain of the small molecules. No 
more. “The ramifications of this are 
just staggering,” says Dowdy. “When 
we have a lab meeting and come up 
with yet another new application for 
this we just laugh - there is just so 
much opportunity.” 
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